Literature DB >> 2472394

Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.

M A Valentine1, K E Meier, S Rossie, E A Clark.   

Abstract

CD20, a B cell integral membrane protein, regulates B cell activation and is differently phosphorylated in resting and activated cells. We have previously shown that CD20 phosphorylation is increased in activated cells and in phorbol ester-treated resting cells. Phosphorylation is also altered by agents which signal B cell proliferation, such as anti-IgM and a B cell growth factor. The present study was designed to address whether protein kinase C (PKC) or other kinases used CD20 as a substrate. When purified PKC was incubated with isolated CD20, both the 35- and 37-kDa CD20 proteins were phosphorylated in vitro. Intact resting B cells were next incubated with the protein kinase inhibitors H-7, H-8, and W-7. No change in basal CD20 phosphorylation was observed in the presence of W-7 and H-8, indicating that the protein cyclic nucleotide-dependent and calmodulin-dependent kinases were not actively phosphorylating CD20. Surprisingly, the PKC inhibitor H-7 increased CD20 phosphorylation at concentrations above 25-50 microM. To assess whether PKC either activated a phosphatase or inactivated a kinase affecting CD20 phosphorylation, tryptic phosphopeptide mapping of CD20 was performed. These studies revealed that addition of phorbol 12-myristate 13-acetate increased phosphorylation of some peptides differing from those which had increased phosphorylation following addition of H-7. Furthermore, signalling through surface immunoglobulin increased phosphorylation of CD20 peptides distinct from those hyperphosphorylated following addition of phorbol 12-myristate 13-acetate. These results demonstrate that 1) CD20 has multiple phosphorylation sites, as predicted from sequence data, and 2) whereas PKC can use CD20 as substrate, at least one other unidentified kinase phosphorylates CD20 in resting cells. Our data also predict that activation of B cells via the antigen receptor (surface IgM) may activate other protein kinases in addition to PKC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472394

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.

Authors:  Alberto Lerario; Filippo Cogiamanian; Chiara Marchesi; Marzia Belicchi; Nereo Bresolin; Laura Porretti; Yvan Torrente
Journal:  BMC Musculoskelet Disord       Date:  2010-07-11       Impact factor: 2.362

2.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Authors:  L Ginaldi; M De Martinis; E Matutes; N Farahat; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

3.  RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.

Authors:  M Tahara; H Tsuboi; S Segawa; H Asashima; M Iizuka-Koga; T Hirota; H Takahashi; Y Kondo; M Matsui; I Matsumoto; T Sumida
Journal:  Clin Exp Immunol       Date:  2016-10-11       Impact factor: 4.330

4.  Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies.

Authors:  Yuichiro Ide; Yutaka Imamura; Satoko Ohfuji; Wakaba Fukushima; Saburo Ide; Chiyo Tsutsumi; Masahisa Koga; Kazuhiro Maeda; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells.

Authors:  Alessandro Camponeschi; Kathrin Kläsener; Timothy Sundell; Christina Lundqvist; Paul T Manna; Negar Ayoubzadeh; Martina Sundqvist; Katrin Thorarinsdottir; Mariele Gatto; Marcella Visentini; Karin Önnheim; Alaitz Aranburu; Huamei Forsman; Olov Ekwall; Linda Fogelstrand; Inger Gjertsson; Michael Reth; Inga-Lill Mårtensson
Journal:  J Exp Med       Date:  2022-07-12       Impact factor: 17.579

6.  Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Authors:  Claudio Galarza; Diana Valencia; Gabriel J Tobón; Luis Zurita; Rubén D Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan C Rueda; Juan-Manuel Anaya
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 7.  Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.

Authors:  Deborah A Thomas; Farhad Ravandi; Michael Keating; Hagop M Kantarjian
Journal:  Leuk Lymphoma       Date:  2009-10

8.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Authors:  Vivek L Patel; Matthieu Mahévas; Soo Y Lee; Roberto Stasi; Susanna Cunningham-Rundles; Bertrand Godeau; Julie Kanter; Ellis Neufeld; Tillmann Taube; Ugo Ramenghi; Shalini Shenoy; Mary J Ward; Nino Mihatov; Vinay L Patel; Philippe Bierling; Martin Lesser; Nichola Cooper; James B Bussel
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

9.  Anti-immunoglobulin M activates nuclear calcium/calmodulin-dependent protein kinase II in human B lymphocytes.

Authors:  M A Valentine; A J Czernik; N Rachie; H Hidaka; C L Fisher; J C Cambier; K Bomsztyk
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.

Authors:  Bin Jiang; Ting Li; Li Guo; Hao Shen; Shuang Ye; Sheng Chen
Journal:  J Clin Rheumatol       Date:  2015-08       Impact factor: 3.517

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.